GlassScriptPhysician profile
Luke Romanow
NPI 1528301116
$818.77
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $77.96 · 2021: $202 · 2022: $206.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $120.81 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $118.31 | 2019-2022 | |
| Alkermes, INC. | $100.05 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $98.95 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $84.35 | 2021-2022 | |
| Abbvie INC. | $77.57 | 2021-2022 | |
| Allergan, INC. | $71.10 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.39 | 2021-2022 | |
| Lundbeck LLC | $32.73 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.99 | 2019 | |
| Neuronetics, INC. | $20.57 | 2019 | |
| Eisai INC. | $17.71 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Romanow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.